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The defense against influenza virus (IV) infections still poses a series of challenges.
The current antiviral arsenal against influenza viruses is in fact limited; therefore, the
development of new anti-influenza strategies effective against antigenically different
viruses is an urgent priority. Bioactive compounds derived from medicinal plants and
fruits may provide a natural source of candidates for such broad-spectrum antivirals.
In this regard, cranberry (Vaccinium macrocarpon Aiton) extracts on the basis of their
recognized anti-adhesive activities against bacteria, may provide potential compounds
able to prevent viral attachment to target cells. Nevertheless, only few studies have so far
investigated the possible use of cranberry extracts as an antiviral tool. This study focuses
on the suitability of a cranberry extract as a direct-acting anti-influenza compound. We
show that the novel cranberry extract Oximacro R© inhibits influenza A and B viruses (IAV,
IBV) replication in vitro because of its high content of A-type proanthocyanidins (PAC-A)
dimers and trimers. Mechanistic studies revealed that Oximacro R© prevents attachment
and entry of IAV and IBV into target cells and exerts a virucidal activity. Oximacro R© was
observed to interact with the ectodomain of viral hemagglutinin (HA) glycoprotein, thus
suggesting the interference with HA functions and a consequent loss of infectivity of IV
particles. Fluorescence spectroscopy revealed a reduction in the intrinsic fluorescence
of HA protein after incubation with purified dimeric PAC-A (PAC-A2), thus confirming
a direct interaction between HA and Oximacro R© PAC-A2. In silico docking simulations
further supported the in vitro results and indicated that among the different components
of the Oximacro R© chemical profile, PAC-A2 exhibited the best binding propensity with
an affinity below 10 nM. The role of PAC-A2 in the anti-IV activity of Oximacro R© was
eventually confirmed by the observation that it prevented IAV and IVB replication and
caused the loss of infectivity of IV particles, thus indicating PAC-A2 as the major active
component of Oximacro R©. As a whole, these results suggest Oximacro R© as a potential
candidate to create novel antiviral agents of natural origin for the prevention of IV
infections.
Keywords: influenza virus, cranberry extract, Oximacro R©, dimeric A-type proanthocyanidins, PAC-A2,
hemagglutinin, antiviral and virucidal activities
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INTRODUCTION
The influenza viruses type A and type B (IAV, IBV) are
widespread major pathogens among human populations and are
responsible for seasonal epidemics and pandemics (Paules and
Subbarao, 2017). Annual influenza epidemics cause worldwide
3–5 million cases of serious disease and up to half a million
deaths among high-risk groups (Molinari et al., 2007; Thompson
et al., 2009), with an even greater impact in developing countries
(Lafond et al., 2016).
Currently, seasonal vaccines represent the most effective
measure to prevent and control IV infections (Houser and
Subbarao, 2015). However, prophylaxis and treatment of IV
infections may also benefit from two classes of licensed drugs:
matrix protein inhibitors and neuraminidase inhibitors (NAIs)
(Govorkova and McCullers, 2013; McKimm-Breschkin, 2013;
Ison, 2015). Among the first, amantadine and rimantadine inhibit
the viral uncoating in endosomes by interfering with the M2
ion channel-mediated acidification (Hay, 1992). However, these
drugs are only effective against IAV, and their use is restricted by
low effectiveness, collateral effects, and the selection of resistance
strains (Hayden and Hay, 1992; Suzuki et al., 2003). On the
other hand, oseltamivir and zanamivir are NAIs that prevent the
release of IV particles from infected cells, and represent the first-
line therapy against influenza infections (McKimm-Breschkin,
2002, 2013; Govorkova, 2013; Ison, 2015). Despite these drugs’
efficacy against both IAV and IBV, the number of circulating
NAI-resistant viruses has greatly increased in the past few years
(McKimm-Breschkin, 2005, 2013). More recently, peramivir,
and laninamivir octanoate have been approved as novel NAIs
for the treatment of influenza, and proposed for a combined
therapy regimen to prevent resistance occurrence (Ikematsu and
Kawai, 2011;Alame et al., 2016). Nevertheless, several strains
that are resistant to both of these new NAIs already have been
isolated (Takashita et al., 2016). Given these facts, the control of
IV infections still presents major challenges, and therefore the
development of alternative anti-IV compounds, both effective
against antigenically different viruses and characterized by new
mechanisms of action, is an urgent priority (Van de Wakker et al.,
2017).
Natural products derived from medicinal plants could be
exploited as candidates for broad-spectrum antivirals, and
polyphenols, flavonoids, glucosides, and alkaloids extracted from
several plants and fruits have shown anti-IV activity (Wang
et al., 2006; Ge et al., 2010; Ha et al., 2014; Bahramsoltani
et al., 2016). Among plant-extracts containing polyphenols, those
rich in A-type proanthocyanidins (PAC-A) obtained from the
American cranberry Vaccinium macrocarpon Aiton (Ericaceae)
exert antibacterial activities on the basis of their recognized
anti-adhesive activity (Gupta et al., 2007; Jepson and Craig,
2008; Shmuely et al., 2012; Blumberg et al., 2013; Krueger
et al., 2013). Therefore, cranberry extracts may also represent
a source of potential compounds that would prevent viral
attachment to target cells as well. Indeed, antiviral activities
of cranberry extracts have been reported against Reovirus
(Lipson et al., 2007), Enterovirus (Su et al., 2010), and even
against IV (Weiss et al., 2005; Oiknine-Djian et al., 2012;
Sekizawa et al., 2013). However, a lack of mechanistic studies
and the standardization of productive processes to maintain
comparable bioactive components concentrations, have limited
the development of cranberry products as antivirals against
IV infections. More recently, we have observed that the novel
cranberry extract Oximacro R©, which is characterized by a high
content of PAC-A, was compelling in the prevention of bacterial
infections of the urinary tract (Occhipinti et al., 2016), and was
able to exert a potent inhibitory activity against replication of
herpes simplex 1 and 2 viruses by inhibiting the attachment of
viral particles to target cells (Terlizzi et al., 2016).
Based on these premises, the aim of this study was to evaluate
the anti-IV activity of Oximacro R©. We show that this extract can
prevent replication of both IAV and IBV by a mechanism that
stems from the inhibition of attachment and entry of IV particles
as a consequence of alterations in hemagglutinin (HA) functions.
Indeed, dimeric PAC-A were identified as the active component
of Oximacro R© that interacts with and affects HA. Together, these
results indicate that Oximacro R© is an attractive candidate to
create novel antivirals for the prevention of IV infections.
MATERIALS AND METHODS
Compounds
The cranberry (V. macrocarpon Aiton) extract Oximacro R©
was obtained by Biosfered S.r.l. (Turin, Italy) as a reddish
powder, and resuspended in Dulbecco’s Modified Eagle Medium
(DMEM; Euroclone) at 10 mg/ml. Purified PAC-A dimer
(PAC-A2) was purchased from Extrasynthese (France) and
dissolved in 96% v/v ethanol (Sigma-Aldrich, United States)
to generate a final concentration of 100 µg/ml. To determine
the total PAC content of Oximacro R©, the Brunswick Labs
p-dimethylaminocinnamaldehyde (BL-DMAC) assay was
performed as previously described by Prior et al. (2010) and
Occhipinti et al. (2016). The content of PAC-A and PAC-B of
Oximacro R© was determined by HPLC-ESI-MS/MS as previously
described by Occhipinti et al. (2016). Fractionation of Oximacro R©
by gel filtration chromatography was performed as described
by Terlizzi et al. (2016). Identification of the phytochemical
composition of purified fractions (1–5) was carried out by MRM
mass spectroscopy (Terlizzi et al., 2016).
Oseltamivir carboxylic acid, the active form of oseltamivir, was
obtained from Santa Cruz.
Cells, Culture Conditions, and Viruses
Madin Darby Canine Kidney cells (MDCK, ATCC R© CCL-34TM)
were propagated in DMEM supplemented with 10% fetal bovine
serum (FBS; Euroclone), 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 U/ml penicillin, and 100 µg/ml streptomycin
sulfate. Infections were performed in the presence of 1 µg/ml of
trypsin TPCK treated from bovine pancreas (Sigma-Aldrich, St.
Louis, MO, United States) and 0.14% of Bovine Serum Albumin
(Sigma-Aldrich, St. Louis, MO, United States).
The influenza A virus strain A/Puerto Rico/8/34 (IAV) and
the influenza B virus strain B/Lee/40 (IBV) were a generous gift
from Arianna Loregian (University of Padua, Italy). IAV and IBV
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were cultured and titrated by plaque reduction assay (PRA) on
MDCK cells as described below. Experiments were performed
under BSL-2 conditions.
Cytotoxicity Assay
Cytoxicity of either Oximacro R© or its purified fractions was
determined on MDCK cells after a 72 h of treatment. The number
of viable cells was measured by MTT as previously described
(Luganini et al., 2008, 2010).
Antiviral Assays
The antiviral activity of Oximacro R©, its purified fractions or PAC-
A2 was determined by PRA. To this end, MDCK cells were seeded
in 24-well plates (3 × 105 cells/well) and after 24 h they were
exposed 1 h prior to infection to increasing concentrations of
either Oximacro R©, its fractions or PAC-A2, and then infected
with IAV or IBV (40 PFU/well). After virus adsorption (1 h
at 37◦C), cultures were incubated in medium containing 0.7%
Avicel (FMC BioPolymer) plus Oximacro R© or its fractions. At
48 h post-infection (h p.i.), the cells were fixed with a solution of
4% formaldehyde in phosphate-buffered saline 1X (PBS) for 1 h at
room temperature (RT) and stained with a solution of 1% crystal
violet. The microscopic plaques count then allowed to define the
concentration of either Oximacro R© or its purified fractions that
produced 50 and 90% reductions in plaque formation (IC50 and
IC90).
For the time-of-addition assay, a modified PRA was
performed. Briefly, MDCK cells were seeded as described
above for PRA, and the following day different Oximacro R©
concentrations were added 1 h before virus adsorption (pre-
adsorption treatment), during virus adsorption (adsorption
treatment), or after adsorption for 48 h (post-adsorption), as
summarized in the scheme depicted in Figure 2. The cells were
infected with either IAV or IBV (40 PFU/well) for 1 h at 37◦C and
then washed with warm medium to remove unbound virions. At
48 h p.i., the plaques were stained as described above.
For viral attachment and entry assays, MDCK cells were
seeded as for PRA and after 24 h cultures were chilled on ice
for 20 min and washed three times with cold medium. For the
attachment assay, chilled MDCK cell monolayers were infected at
4◦C for 2 h with either IAV or IBV (40 PFU/well) in the presence
of different concentrations of Oximacro R© (20-10-5-2.5 µg/ml).
After viral adsorption, the cells were washed twice with warm
medium and incubated with medium-containing 0.7% Avicel for
48 h at 37◦C. The IV plaques were then stained as described
above.
For the entry assay, MDCK cell monolayers were infected
with either IAV or IBV (40 PFU/well) for 2 h at 4◦C. After
adsorption, infected cultures were washed with cold medium, and
different concentrations of Oximacro R© (20-10-5-2.5 µg/ml) were
added for 2 h at 37◦C to allow viral entry. Then, cell monolayers
were treated with cold acidic glycine buffer (100 mM glycine,
150 mM NaCl, pH 3) for 30 s to remove adsorbed virions, washed
twice with warm medium, and then incubated with medium-
containing 0.7% Avicel for 48 h at 37◦C. The plaques were then
stained as described above.
To evaluate the effect of Oximacro R© on IV infectivity, 2× 104
PFU of either IAV or IBV were incubated with 25 µg of
Oximacro R© for 0, 60, 120, or 180 min at either 37◦C or at 4◦C.
The, viral suspensions were diluted 100-fold in medium to lower
the concentration of Oximacro R© below that required for antiviral
activity, and residual IV infectivity was measured by PRA as
described above.
Immunoblotting and SDS–PAGE
To investigate the interaction of Oximacro R© with IAV
Hemagglutinin (HA), aliquots of purified recombinant HA
subtype H1N1 (A/Puerto Rico/8/1934) ectodomain (1–528 aa)
(Sino Biological-11684V08H50) were incubated at 37◦C for
different times with Oximacro R©. Then, mixtures were treated
with SDS sample buffer, fractionated through 10% SDS–PAGE,
and analyzed either by staining with Coomassie blue or
immunoblotting using the rabbit anti-HA antibody (PA5-34929,
ThemoScientific). Immunocomplexes were detected with a
goat anti-rabbit Ig Ab conjugated to horseradish peroxidase
(Life Technologies, Carlsbad, CA, United States) and visualized
by enhanced chemiluminescence (Western Blotting Luminol
Reagent, Santa Cruz).
Fluorescence Quenching Assay
PAC-A2 (Extrasynthese) was tested for its ability to bind
to HA using fluorescence quenching. In this assay, PAC-A2
quenches the protein’s intrinsic fluorescence produced by the
tryptophan fluorophores. Measurements were performed
in a quartz cuvette using a fluorescence spectrometer
LS55 (PerkinElmer). Fluorescence emission spectra were
monitored in the 295–500 nm range using a scan-rate of
200 nm/min upon excitation at 290 nm. The excitation and
emission slits were arranged to 8.0 and 10.0 nm, respectively.
The protein was dissolved in PBS buffer (pH 7.4) at a
concentration of 1.2 µM. Samples were measured in the
absence and presence of PAC-A2, following 1 h 25◦C. Data
were normalized by subtracting the contribution of PAC-A2
fluorescence.
Ligand and Protein Structure Preparation
for Docking Experiments
Ligand and protein structures were prepared using the YASARA
structure package (Krieger et al., 2002). YASARA, version
17.5.9, has all the functions embedded useful to predict and
validate macromolecular structures, including ligand docking
and highly accurate force fields with knowledge-based potentials.
Hydrogens were added to both the crystal structure of
IAV HA A/Puerto Rico/8/34 (PDB ID: 1RU7; Gamblin
et al., 2004) and ligand molecules. All the structures were
then optimized through energy minimization using preparing
the molecules as previously reported (Catucci et al., 2012;
Gao et al., 2016). AMBER 03 force field was employed
throughout all simulations. The cutoff for van der Waals
interactions was 7.86 Å and the Particle Mesh Ewald (PME)
algorithm was applied to compute the long range electrostatic
interactions.
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In silico Docking
In the docking experiment, the substrate is originally outside
the simulation cell and is placed inside the cell by exploiting
the Autodock Lamarckian Genetic algorithm, resulting in a
series of binding modes classified by the binding energy outputs
(Gao et al., 2016). Among these binding modes, the complex
protein-ligand bearing the highest binding energy, calculated by
YASARA as the mechanical energy required for disassembling
a whole into separate parts (where positive energies indicate
stronger binding and negative energies equate to no binding),
was selected and further refined by local docking. After docking
the results were sorted by binding energy and corresponding
predicted Kd.
The chemical structures of PAC-A dimers (PAC-A2), PAC-
B-2, Kuromaninin, Delphinidin 3-glucoside, Rutin, Quercetin,
and Isorhamnetin were obtained from Pubchem. Structures were
optimized in terms of molecular geometry optimization using
YASARA. The ligands were docked to the crystal structure of
IAV HA A/Puerto Rico/8/34 (PDB ID: 1RU7; Gamblin et al.,
2004) using the AutoDock algorithm (Morris et al., 1998, 2009)
embedded in YASARA. To explore all the possible solutions,
999 runs of global docking were performed using a simulation
cell package and 100 runs of flexible docking. A simulation cell
(75 Å × 75 Å × 75 Å) was built to incorporate the extracellular
domain of HA. YASARA’s scoring function generated both
binding energies and predicted dissociation constant (kd) values.
Distinct complex conformations were classified when they
differed by at least 5.0 Å RMSD.
Statistical Analysis
All results were obtained by experiments performed in duplicate
in at least three independent biological replicates. Statistical
analysis by the one-way ANOVA test was performed using the
PRISM software version 5.0 (GraphPad Software, Inc.).
RESULTS
Oximacro R© Contains a High Percentage
of PAC-A
The total PAC content of Oximacro R© was in line with the values
declared in the CoA (366.06 mg/g± 4.96). Furthermore, analysis
by HPLC-ESI-MS/MS revealed a high percentage content of total
PAC-A (86.72% ± 1.65), of which the majority corresponded to
PAC-A dimers, and only a small amount was of PAC-A trimers.
Fractionation of Oximacro R© by Sephadex LH-20
chromatography produced five major fractions whose
chemical characterization highlighted the presence of different
phytochemicals, such as anthocyanins, flavonoids, and PACs.
As shown in Supplementary Table 1, fraction 1 contained
delphinidin, and cyanidin glycosides; fraction 2 was composed
of quercetin and isorhamnetin; fractions 3 and 4 were composed
most of PAC-A dimers and of small amounts of PAC trimers;
fraction 5 did not show detectable compounds. Oximacro R© and
its fractions 1–5 were then analyzed for anti-IV activity.
Oximacro R© and Its PACs-A Inhibit IAV and
IBV Replication
Treatment with Oximacro R© inhibited both IAV and IBV
replication in MDCK cells in a concentration-dependent
manner (Figure 1). The calculated IC50 and IC90 values
were 4.5 ± 0.2 µg/ml and 10.4 ± 0.2 µg/ml for IAV, and
4.5 ± 0.5 µg/ml and 9.7 ± 0.5 µg/ml for IBV, respectively. The
50% cytotoxic concentration (CC50) was 141 ± 0.8 µg/ml, thus
indicating that the antiviral activity of Oximacro R© did not stem
from a non-specific cytotoxicity. The selectivity index for IAV and
IBV (CC50/IC50) was therefore 31.1 and 31.3, respectively.
For comparison, oseltamivir, an approved NAI for the
treatment of influenza infections, showed against the tested IV
strains, IC50 of 0,017 µg/ml for IAV and of 0.22 µg/ml µg/ml
FIGURE 1 | Antiviral activity of Oximacro R© against influenza A and B viruses.
MDCK cell monolayers were infected with either IAV or IBV (40 PFU/well), and,
where indicated, the cells were treated with increasing concentrations of
Oximacro R© 1 h before, during virus adsorption, and after adsorption
throughout the experiment. At 48 h p.i., plaques were stained and
microscopically counted. The mean plaque counts for each concentration are
expressed as a percentage of the mean plaque count for the control virus.
The number of plaques was plotted as a function of Oximacro R©
concentration; concentrations producing 50 and 90% reductions in plaque
formation (IC50 and IC90) were thus determined. Data represent means ± SD
(error bars) of three independent experiments performed in duplicate.
Statistical analysis was performed by comparing IAV and IBV replication
curves. ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05. To determine cell viability,
MDCK cells were exposed to increasing concentrations of Oximacro R©. After
3 days of incubation, the number of viable cells was determined by the
3-(4,5-imethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method.
TABLE 1 | Antiviral activity of Oximacro R© fractions against IAV and IBV.
Fraction CC50 (µg/ml) IC50 (µg/ml)
IAV IBV
1 >200 >50 >50
2 >200 >50 >50
3 149.7 ± 3.1 5.02 ± 1.2 6.02 ± 1.2
4 136.4 ± 2.4 3.24 ± 1.4 4.07 ± 1.8
5 >200 >50 >50
IC50 and CC50 values are indicated.
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for IBV, respectively, and consistent with a previous report (Shin
et al., 2017).
To pinpoint the active phytochemical of Oximacro R© that
was responsible for its inhibitory activity, antiviral assays were
performed with purified fractions obtained through fractionation
of Oximacro R©. Analysis of the fractions’ anti-IV activity identified
fractions 3 and 4 as having inhibitory activity against IAV and IBV
(Table 1), thus indicating that the components responsible for the
antiviral activity of Oximacro R© were PAC-A dimers and trimers.
Oximacro R© Targets Early Phases in the IV
Replication Cycle
To understand which phase of the IV replicative cycle is
targeted by Oximacro R©, time-of-addition assays were carried out
in accordance with the scheme depicted in Figure 2. Briefly,
Oximacro R© was added: prior to IV adsorption (pre-adsorption
stage, from -2 to -1 h prior to infection); during infection
(adsorption stage, from -1 to 0 h); or after viral adsorption (from
0 to 48 h p.i.). Evaluation of the IC50 indicated that Oximacro R©
was more effective if added either in the pre-adsorption (IC50
of 4.7 µg/ml for IAV and 4.2 µg/ml for IVB, respectively) or
adsorption phases (IC50 of 4.4 µg/ml for IAV and 5.0 µg/ml for
IBV, respectively) than after infection. In fact, addition of the
extract at the end of the adsorption period increased the IC50
to more than 20 µg/ml for both IAV and IBV, thus indicating
that Oximacro R© was more active against the early stages of IV
replication cycle, such as attachment and entry. To investigate
this possibility further, selective attachment and entry assays
were performed. In the attachment assays, prechilled MDCK
cells were infected with either IAV or IBV in the presence of
different concentrations of Oximacro R© for 2 h at 4◦C, so that to
enable the attachment of IV particles, but not their entry into
target cells. Oximacro R© and unattached virions were then washed
away, and the remaining IV infectivity was evaluated at 48 h p.i.
As shown, in Figure 3A, Oximacro R© inhibited the attachment
of both IAV and IBV in a concentration-dependent manner.
Next, to investigate the inhibitory activity of Oximacro R© on IV
entry, prechilled MDCK monolayers were infected with IV at
4◦C for 2 h to enable viral attachment but not entry. Different
concentrations of Oximacro R© were then added and infected
cultures were incubated at 37◦C for 2 h to allow entry of adsorbed
IV particles. At the end of this incubation period, IV viruses still
bound to the cells were inactivated by briefly treating with acidic
glycine buffer, and the remaining IV infectivity was evaluated
at 48 h p.i. As depicted in Figure 3B, Oximacro R© prevented
FIGURE 2 | Oximacro R© acts in an early stage of IV-replicative cycle. A schematic summary of the time-of-addition experiment is shown at the top of the figure.
Accordingly, MDCK cell monolayers were left untreated or treated with different concentrations of Oximacro R© from -2 to -1 h (pre-adsorption) (A,D) or from -1 to 0 h
(adsorption) (B,E) before infection with IAV or IBV (40 PFU/well). In the post-adsorption treatment (from 0 to 48 h p.i.) (C,F), untreated and infected cells were
exposed to the same concentrations of Oximacro R© as indicated in the scheme on the top and were infected with IAV or IBV (40 PFU/well) at -1 h p.i. At 48 h p.i.,
plaques were stained and microscopically counted. Data represent means ± SD (error bars) of three independent experiments performed in duplicate. For each
experimental condition, statistical analysis was carried out by comparing treated samples with the untreated control (100% infection). ∗∗∗p < 0.001, ∗∗p < 0.01, and
∗p < 0.05.
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FIGURE 3 | IV attachment and entry is prevented by Oximacro R©. (A) Oximacro R© affects IV attachment. Prechilled MDCK cells were infected with precooled IAV or
IBV (40 PFU/well) in the presence of different concentrations of Oximacro R© (20-10-5-2.5 g/ml) at 4◦C for 2 h. After viral adsorption, the cells were washed and
overlaid with 0.7% Avicel. At 48 h p.i., viral plaques were stained and microscopically counted. The results shown are means ± SD (error bars) from three
independent experiments performed in duplicate. (B) Oximacro R© inhibits IV entry. Prechilled MDCK cells were infected with IAV or IBV (40 PFU/well) for 2 h at 4◦C to
allow virion attachment to the cells. After adsorption, the cells were treated with different concentrations of Oximacro R© (20-10-5-2.5 µg/ml) for 2 h at 37◦C, prior to
inactivation of extracellular virus with acidic glycine buffer for 30 s at RT. After further washing, the cells were incubated with medium-containing 0.7% Avicel. At 48 h
p.i., viral plaques were stained and microscopically counted. The results shown are means ± SD (error bars) of three independent experiments performed in
duplicate. ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with the 100% virus infectivity of untreated controls.
the entry of both IAV and IBV in a concentration-dependent
manner. Together, these results revealed that Oximacro R© is able
to interfere with both viral attachment and entry, therefore
suggesting its suitability as an early-acting inhibitor of IV
replication.
Oximacro R© Has Virucidal Activity
Against IV
The observed inhibition of IV attachment and entry could stem
from damages caused by Oximacro R© to IV particles prior to their
interactions with host cells. To verify this hypothesis, suspensions
of IAV or IBV particles were incubated with Oximacro R© (25 g/ml)
for 0, 60, 120, and 180 min at either 37◦C or at 4◦C. After
incubation, mixtures were diluted to reduce the concentration of
Oximacro R© well below that which prevents virus attachment and
entry (Figure 3), and then the residual IV infectivity of diluted
samples was measured by PRA on MDCK cells. Figure 4A shows
that the incubation of IV particles with Oximacro R© at 37◦C,
determined a complete loss in infectivity of IVA and IBV after 180
and 120 min of incubation, respectively. In contrast, incubation at
4◦C, even at longer times, led to no detectable loss of IV infectivity
(Figure 4B), thus suggesting that Oximacro R© exhibits time-
dependent and temperature-dependent inactivation of infectious
IV (i.e., virucidal activity). Likewise, a virucidal activity against
IAV and IBV was observed for fraction 4, the richest in A type
PAC dimers and trimers (data not shown). Thus, these results
suggest that the anti-IV activity of Oximacro R© stems from its
ability to affect IV virions, thus impairing their attachment and
entry into host cells.
Oximacro R© Interferes With IV
Hemagglutinin
Influenza virus hemagglutinin (HA) is responsible for both
the IV attachment and entry by mediating both the initial
interaction with cell receptors containing sialic acid, and the
fusion between endosome membranes and the viral envelope.
Because Oximacro R© decreased the infectivity of IV particles
(Figure 4), we then investigated whether it targets HA, thus
impairing its functions in the early stages of the IV replication
cycle. To this end, aliquots of purified recombinant HA from the
A/Puerto Rico/8/34(H1N1) strain, produced in baculovirus, and
corresponding to the ectodomain of the glycoprotein (1–528 aa)
(Figure 5A), were mixed with increasing concentrations of the
extract and incubated at 37◦C. Figure 5B shows that the exposure
of purified HA to Oximacro R© caused a reduction in the amount of
HA protein band, and altered its electrophoretic mobility with the
occurrence of an evident smear toward high molecular weights
at the highest Oximacro R© concentrations. Similarly, the exposure
of HA to Oximacro R© for different times determined a time-
dependent reduction of the HA protein band, and the appearance
of a protein smear with lower electrophoretic mobility compared
with the untreated control. Thus, Oximacro R© was able to interact
with HA in a concentration- and time-dependent fashion. These
findings suggest that interactions between Oximacro R© and IV HA
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FIGURE 4 | Incubation of IV particles with Oximacro R© abrogates infectivity.
IAV or IBV (2 × 104 PFU) were incubated at 37◦C (A) or at 4◦C (B) for various
lengths of time in the absence of Oximacro R© (NT) (closed circles) or with 25 g
of the Oximacro R© (closed squares). After incubation, the samples were diluted
to reduce Oximacro R© concentration below that which inhibits IV attachment
(0.25 µg/ml). Plaques were microscopically counted, and the mean plaque
counts was expressed as PFU/ml on a log10 scale. The data shown represent
means ± SD (error bars) of three independent experiments performed in
duplicate. ∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05 compared with the titer
of untreated controls (NT).
may hamper its functions in virus attachment and entry, and
underlie the overall antiviral activity of Oximacro R©.
PAC-A2 Interacts With HA and Exerts a
Virucidal Activity
Fluorescence spectroscopy is widely used to investigate
enzyme–ligand interactions, because alteration of the
fluorescence emission spectrum of proteins can be used to
detect conformational changes, binding to ligands, or unfolding
processes. In this regard, it has been reported that PACs can
reduce the signature fluorescence of bound proteins, thus
fluorescence quenching can be used to demonstrate the binding
of PACs to proteins (Soares et al., 2009; Gonçalves et al.,
2010a,b). Here, we applied fluorescence spectroscopy to test our
hypothesis that the binding of Oximacro R© to HA is mediated
by its PAC-A dimers. The recombinant extracellular domain
of our test H1N1 HA (A/Puerto Rico/8/1934) contains nine
tryptophans, and the emission maximum of its fluorescence
spectrum occurs at 342 nm (Figure 6). The addition of 25 µM
of purified PAC-A dimers (PAC-A2) caused a reduction in
the intrinsic tryptophan fluorescence of HA, but overall it
did not markedly modify the shape of the emission spectrum
(Figure 6). Thus, this result sustains the hypothesis that PAC-
A2 binds to HA; moreover, since there was no considerable
change in the emission maximum of the intrinsic protein
fluorescence, it implies that the interaction does not bring
about significant conformational change in the overall structure
of HA.
To support the occurrence of interactions between HA and
PAC-A2 further, in silico docking simulations were performed.
Since PAC are known to bind protein structures at multiple
binding sites (Hagerman and Butler, 1981), all the possible
solutions were included in the analysis to provide a possible
mechanism of interaction between the small PAC-A2 dimer
molecule and the HA structure. Using the crystal structure of HA
(A/Puerto Rico/8/1934, PDB ID: 1RU7) of our tested IAV strain,
docking analysis revealed that PAC-A dimers binds to the internal
grooves of the HA structure first (Figure 7A, left panel), and
subsequently to the surface of the HA structure (Figure 7A, right
panel). The best binding pose is shown in Figure 7B, where HA
residues (PHE 299, TRP 234, and ASN 210) forming hydrogen
bonds to PAC-A2 are highlighted.
We then performed further in silico docking analysis tests
to investigate the ability of the different components present
in Oximacro R© fractions (Supplementary Table 1) to interact
in silico with the crystal structure of HA. Of the different
Oximacro R© components tested, the PAC-A dimer was identified
as the molecule with the best docking capability. In fact, when
comparing the theoretical dissociation constants for the top
100 scoring poses (Figure 7C, left panel), clustered to separate
complexes with a RMSD higher than 5.0 Å, the simulated
PAC-A2-HA complexes formed most favorably with an affinity
under 10 nM. Furthermore, the distribution of all the docking
data (Figure 7C, right panel) confirms that even the worst
100 theoretical complexes (out of 999) are still much more
likely to bind HA efficiently than any of the other Oximacro R©
components.
These in silico docking simulations are therefore consistent
with the fluorescence analysis (Figure 6) and support the
hypothesis that PAC-A2 constitute the chemical component of
Oximacro R© responsible of binding to and altering HA.
To verify experimentally the role of PAC-A dimers as
antiviral molecules, we tested purified PAC-A2 in some antiviral
assays against IV. As shown in Figure 8A, PAC-A2 produced
a concentration-dependent inhibition of both IAV and IBV.
However, its IC50 against both IAV and IBV was higher than
that of Oximacro R©: 14.8 µg/ml for IAV, and 11.2 µg/ml for IBV,
respectively. This result may suggest the occurrence of a possible
synergistic effect of PAC-A2 with PAC-A trimers, since the IC50
of fraction 4, the richest in PAC-A dimers and trimers was similar
to that of Oximacro R© (Table 1). Moreover, when tested on IV
particles’ infectivity (Figure 8B), PAC-A2 determined a complete
loss of IAV and IBV infectivity after an incubation of IAV and
180 min at 37◦C, which indicated the ability of PAC-A2 to
bind to IV particles and thereby impair their infectivity prior to
attachment to host cells. Altogether, these results suggest PAC-A
dimers as the active components of Oximacro R© responsible of the
majority of the overall anti-IV activity of the extract.
DISCUSSION
New anti-influenza molecules need to be continually developed,
and this can be done through the adoption of a variety of
approaches, such as: (a) improvement of existing drugs; (b)
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FIGURE 5 | Oximacro R© interacts with the recombinant extracellular domain of IAV HA. (A) SDS–PAGE and immunoblot analysis of recombinant IAV-HA glycoprotein.
Purified HA protein was analyzed on 10% SDS-polyacrylamide gels. Gel was either stained with Coomassie blue or analyzed by immunoblotting with an anti-HA IAV
mAb. Left panel: Coomassie blue-stained gel of 1 g of purified recombinant HA-IAV. Right panel: Immunoblot analysis with 200 ng of the same sample as in the left
panel. (B,C) Oximacro R© interacts with recombinant HA in a concentration- (B) and time-dependent (C) manner. (B) Purified recombinant HA-IAV (1 g) was incubated
at 37◦C with medium or increasing amounts of Oximacro R© for 3 h, and then mixtures were analyzed by SDS–PAGE. (C) Purified recombinant HA-IAV (1 g) was
incubated at 37◦C for various lengths of time with medium or 6 g of Oximacro R©. At 30 min, 1, 2, and 3 h of incubation, mixtures were analyzed by SDS–PAGE. Gels
were then stained with Coomassie blue. Sizes are indicated in kilodaltons.
FIGURE 6 | PAC-A2 determines quenching of HA-IAV fluorescence.
Recombinant HA-IAV was resuspended in PBS buffer (pH 7.4) at a
concentration of 1.2 µM. Fluorescence of HA-IAV aliquots were measured in
the absence (blue curve) and presence (orange curve) of 25 M PAC-A2 after
incubation for 1 h at 25◦C. Fluorescence emission spectra were monitored in
the 295–500 nm range using a scan-rate of 200 nm/min upon excitation at
290 nm. Data reported were normalized by subtracting the PAC-A2
fluorescence contribution.
selection and validation of new viral molecular targets; (c)
the search for molecule able to inhibit early events in the
replication cycle and thus to prevent the establishment of
infections; (d) the search for agents able to modulate the
host antiviral defense responses; and (e) exploitation of the
synergistic effects of compound mixtures acting on different
molecular targets (Loregian et al., 2014). Regardless of the
approach adopted, a critical prerequisite for developing anti-
IV compounds is the requirement for effectiveness against
antigenically diverse viruses. In this scenario, natural products
derived from plant extracts could be a source of candidates for
broad-spectrum anti-influenza compounds able to interfere with
early phases of the replication cycle of antigenically different IV
viruses. This approach, however, is complicated by a number
of hurdles that must be overcome; they include: the production
of highly active and standardized extracts; identification of the
active components responsible for the antiviral activity; and
characterization of the mechanism(s) of action, which are often
related to a synergistic cooperation among different components.
In this study, we report that Oximacro R©, a cranberry extract
characterized by a remarkable amount of PAC-A, exerts a potent
dose-dependent antiviral activity against IAV and IBV by a
virucidal mechanism that involves the interaction with viral
particles, and the subsequent impairment of the HA-mediated
adsorption and entry into host cells.
Many phytochemicals of relatively low molecular weight, such
as polyphenols, flavonoids, terpenes, glucosides, and alkaloids
extracted from different plants have been shown to be endowed
with an antiviral activity against IV (Wang et al., 2006; Song et al.,
2014; Grienke et al., 2016). In particular, among the polyphenols-
enriched plants extracts active against IV (Droebner et al., 2007;
Mori et al., 2008; Gangehei et al., 2010; Yang et al., 2014),
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FIGURE 7 | PAC-A2 interacts with HA in an in silico model. (A) Binding of PACA2 to HA-IAV. Crystal structures of HA-IAV (A/Puerto Rico/8/34-PDB ID: 1RU7) and
PAC-A2 were docked using the AutoDock algorithm, embedded in YASARA. Docking analysis revealed that PAC-A2 binds within the internal grooves of the HA
structure first (left panel) and subsequently to the surface of the structure (righ panel). (B) Best pose of PAC-A2 to HA-IAV. This represents the best complex obtained
after 999 docking runs. The HA-IAV structure is represented in blue; PAC-A2 is in cyan; residues forming hydrogen bonds to the ligand are in green; and hydrogen
bonds are in yellow. (C) PAC-A2 is the Oximacro R© component that binds best to HA. Chemical structures of different components of Oximacro R© were subjected to
docking analysis. PAC-A2 (A2), PAC-B2 (B2), Delphinidin 3-glucoside (DE), Isorhamnetin (IS) Kuromanin (KU), Quercetin (QU), and Rutin (obtained from Pubchem)
were docked with HA. In the left panel, the distribution of the binding constants of the top 100 scoring complex clusters is shown; in the right panel, the distribution
of the worst 100 scoring complexes is shown. In the right panel, Rutin is not shown because its binding constant was >30 µM.
some have been proposed as adjuvant components in therapeutic
regimens based on licensed anti-influenza drugs (Bahramsoltani
et al., 2016). Nevertheless, the mechanism of action of most of
these polyphenol-enriched extracts remains to be defined.
In this regard, it has been observed that the Rumex acetosa
polyphenol-enriched extract exerts an inhibitory activity against
IAV replication by impairing the attachment of viral particles
to target cells (Derksen et al., 2014). The B-type PAC dimer
(procyanidin B2-di-gallate, PAC-B2) was characterized as the
primary antiviral compound of the R. acetosa extract and shown
to cause HA oligomerization; thus, suggesting an association
between the loss of influenza A virus infectivity and HA
alterations, which is consistent with the predicted ability of PAC-
B2 to bind in silico to HA (Derksen et al., 2014). Thus, it was
proposed that PAC-B2 of the R. acetosa extract can inhibit IAV
attachment by directly interacting with virions and affecting HA
in a manner that prevents the binding of viral particles to cell
receptors (Derksen et al., 2014).
Moreover, it has been reported that non-dialyzable material
(NDM) from cranberry juice prevents IV infectivity and
attachment (Weiss et al., 2005) and interferes with the enzymatic
activity of viral neuraminidase (Oiknine-Djian et al., 2012).
In line with this observation, it has also been shown that
pomegranate-derived polyphenols exert a virucidal activity
against IV by interacting with HA and NA (Sundararajana et al.,
2010).
Likewise, here, we report that Oximacro R© abolishes both
IAV and IBV replication through a virucidal mechanism that
involves its direct binding to HA, as indicated by the alteration of
electrophoretic mobility of the HA ectodomain upon incubation
with Oximacro R© (Figure 5), and that such interaction can be
mediated by PAC-A2 present in the extract (Figure 6). However,
our direct comparison between PAC-A2 and PAC-B2 by in silico
docking simulations showed a lower binding affinity to HA of the
latter (Figure 7).
Taken together, these findings support the view that
polyphenols derived from different plants are able to bind with
a certain degree of propensity to HA and NA on the IV envelope.
The observed capability of PACs contained in extracts of
R. acetosa (Derksen et al., 2014) or V. macrocarpon (this study)
to interact with and affect IV HA, could be a consequent to the
natural ability of polyphenols to bind and aggregate proteins
(Charlton et al., 2002; Ebraihimnejad et al., 2014). Dealing
with possible molecular mechanisms behind this PAC’s effect,
it has been proposed that different types of chemical linkages,
such as hydrogen bonding, electrostatic interactions, and even
covalent bonds may contribute to the formation of protein-
PAC complexes (Ebraihimnejad et al., 2014). In this regard,
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FIGURE 8 | Purified PAC-A2 inhibits IV replication by causing loss of virion
infectivity. (A) PAC-A2 inhibits replication of IAV and IBV. MDCK cell were
infected with either IAV or IBV (40 PFU/well), and, where indicated, the cells
were treated with increasing concentrations of PAC-A2 1 h before, during
virus adsorption, and after adsorption throughout the experiment. At 48 h p.i.,
plaques were stained and microscopically counted. To determine cell viability,
MDCK cells were exposed to increasing concentrations of PAC-A2, and the
number of viable cells was determined by the MTT method. Statistical analysis
was accomplished by comparing IAV and IBV replication curves.
∗∗∗p < 0.001, ∗∗p < 0.01, and ∗p < 0.05. (B) Treatment with PAC-A2
abolishes the infectivity of IV particles. IAV or IBV (2 × 104 PFU) were
incubated at 37◦C (A) or at 4◦C (B) for various lengths of time in the absence
(closed circles) or in the presence of 50 µg of PAC-A2 (closed squares). After
incubation, the samples were diluted to reduce PAC-A2 below that which
inhibits IV replication and the residual infectivity assessed by plaque assay.
The mean plaque counts were expressed as PFU/ml on a log10 scale. The
data shown represent means ± SD (error bars) of three independent
experiments performed in duplicate. ∗∗∗p < 0.001, ∗∗p < 0.01, and
∗p < 0.05 compared with the titer of untreated controls (NT).
we observed that the exposure of HA-Oximacro R© complexes
to boiling in SDS sample buffer did not abrogate Oximacro R©-
induced alterations of HA’s electrophoretic mobility (Figure 5).
Thus, it is possible that the incubation of Oximacro R© with the
ectodomain of HA may result even in covalent bonding between
the two partners. Moreover, our docking simulations (Figure 7B)
predicted the formation of three hydrogen bonds between the
PAC-A2 and Phe99, Asn210, and Trp234 of HA, with a computed
binding energy of 14.13 kcal/mol and a dissociation constant of
44.04 pM. Together, the formation of both hydrogen and covalent
bonds between the reactive quinone groups of PAC-A dimers and
trimers (Ebraihimnejad et al., 2014) and HA may eventually lead
to extensive crosslinking of the IV glycoprotein, thus resulting
in smearing and reduction of intensity of the HA protein band
as observed in interactions experiments with the purified HA
ectodomain (Figure 5). However, it remains to establish whether
these HA’s alterations stem from the binding of PAC-A to
specific domains of the IV glycoprotein, or whether PAC-A of
Oximacro R© simply “upholster” HA surfaces (Figure 7A) and,
in this manner, they lead to the inhibition of HA functions in
the initial stages of the IV replication cycle. In this regard, our
docking simulations also suggested that PAC-A2 binds more
strongly to the central HA groove, as confirmed by the top 100
possible poses (Figure 7C, left panel). Based on this observation,
a predicted binding mechanism would entail an initial binding
of PAC-A2 to the HA groove and then, once all the highest
affinity sites have been saturated, the PAC-A2 would bind to other
residues on HA surfaces (Figure 7C, right panel).
Overall, the described mechanism of action of Oximacro R©
against IV advocates its potential application in the prevention
of influenza infections. It is therefore possible to envisage that
a local application of Oximacro R© in the upper respiratory tract,
administered in the form of either tablets/chewing gums or
through inhaling devices, would allow the active PAC-A to
inactivate infecting virus, thus preventing the occurrence of an
infection. This proposal may be sustained also by the high safety
profile that many formulations of dried cranberry extracts have
shown in their widespread use to prevent urinary tract infections
(UTIs) (Jepson and Craig, 2008; Blumberg et al., 2013). However,
the development of Oximacro R© as anti-influenza aid asks its
evaluation in animal models of IV infections, to determine
whether it should be proposed as a novel active ingredient
of broad-spectrum anti-IV agents of natural origin suitable to
prevent IV infections.
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